BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ)
$2.3 -0.01 (-0.4329%)
Analysed BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) News Sources
Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans
11-05-2026
yahoo.com
BDTX Shares Gain 11% in a Week: Here's What You Should Know
11-05-2026
yahoo.com
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
19-05-2026
yahoo.com
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
21-05-2026
yahoo.com
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
21-05-2026
marketbeat.com
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
22-05-2026
yahoo.com
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
25-05-2026
yahoo.com
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
27-05-2026
yahoo.com
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
27-05-2026
yahoo.com
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
27-05-2026
yahoo.com
What is the current price of BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ)?
The current price of BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) is $2.3.
BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) since the previous trading day is $-0.01.
BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) since the previous trading day is -0.4329%.
What is the most recent average sentiment score for BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ)?
The most recent average sentiment score for BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ)?
The most recent sentiment for BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ) is .
SEC-8K** Filing Available For BLACK DIAMOND THERAPEUTICS I (BDTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.